Indian drugmaker Zydus Cadila has made its entry into the US specialty prescription market with the acquisition of Sentynl Therapeutics, a pharma company specialized in marketing of products in the pain management segment.
The transaction will be earnings per share (EPS) accretive, the company stated. Although financial terms of the transaction were not disclosed, ahead of the announcement, media reports on Wednesday suggested the company was all set to buy Sentynl for $171 million.
With this acquisition, Zydus makes a foray into the specialty pain market in the US valued at $8 billion. It gains access to the specialty distribution network and a large prescriber base. Sentynl provides healthcare professionals with treatment solutions that enable them to meet the needs of individual patients. This acquisition will also enable the Zydus group to leverage its existing assets in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze